Mesoblast Limited
HealthcareNASDAQ:MESO · NASDAQ Global Select
-$0.19 today
Vol 0.11M · Avg 0.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-17.1%
avg -14.7%
ROIC
-8.5%
avg -10.3%
ROA
-13.0%
avg -10.8%
Analysis
ROIC is currently the strongest return metric at -8.5% versus its period average of -10.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Silviu Itescu FACP FACRA FRACP MBBS | Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director | $1.68M | — | 69 | $0.00 | <0.01% |
Eric A. Rose | Chief Medical Officer & Executive Director | $893,151.00 | — | 75 | $6.03M | 4.69% |
Fiona See | Senior Vice President & Head of Translational Research | — | — | — | — | — |
Paul J. Simmons | Scientific Advisor to the Chief Executive Officer | — | — | 67 | — | — |
Daniel Devine | Head of Special Projects | — | — | — | — | — |
James Michael O'Brien | Chief Financial Officer | — | — | 60 | $123,220.00 | 0.10% |
Justin Horst | Head of Manufacturing | — | — | — | — | — |
Marcelo Santoro | Chief Commercial Officer | — | — | — | — | — |
Paul Hughes BPHARM | Global Head of Corporate Communications & Joint Company Secretary | — | — | — | — | — |
Peter T. Howard | General Counsel & Corporate Executive | — | — | 58 | — | — |
Geraldine Storton | Head of Regulatory Affairs & Quality Management | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
26
$19.95M
Sells
0
$0.00
Net Sentiment
+$19.95M
Net buying
Most Active
George Gregory
26 transactions
1–10 of 26
Analysis
Insiders reported 26 buys worth $19.95M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $19.95M. George Gregory was the most active insider with 26 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -14.7% | +27.3% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -14.7% over three years. Forward estimates point to Revenue at +27.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
Galapagos N.V.
GLPG
$1.84B
uniQure N.V.
NASDAQ:QURE
$1.74B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
Who manages MESO?
Mesoblast Limited (MESO) lists 11 active executives. The top listed executive is Eric A. Rose, Chief Medical Officer & Executive Director.
Are MESO insiders buying or selling?
Recent insider activity shows net buying of $19.95M.
Explore More
Continue the stock analysis
Jump to another research area for this company.